Strong growth, validation batches mask base business headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit FY27 double-digit growth by Q2. Capex tracking ₹1,223 Cr in H1 towards ₹1,400 Cr guidance. Three projects' commercialization timing withheld due to CDMO confidentiality.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Divi's delivered a stellar 35.4% revenue and 63.6% PAT growth, far exceeding the prior 'double-digit growth assured' guidance. Three major capex projects in final validation stages and a 60-70-project pipeline underpins the long-term narrative. However, management disclosed that ~50% of custom synthesis growth is driven by validation batches—a temporary driver that will normalize post-commercialization. Combined with supply chain headwinds, forex losses (₹20 Cr), and solvent price pressures, the base business outside validation work is flatter than headline growth suggests. Guidance was reaffirmed, not raised; regulatory approval timelines for the three projects remain uncertain.
₹3676 Cr
Revenue · +35.4% YoY₹1127 Cr
Reported PAT · +63.6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
32% YoY revenue growth in Q2
MET35.4% YoY (₹3,676 Cr vs ₹2,709 Cr prior year)
64% PAT growth in Q2
MET63.6% PAT growth (₹1,127 Cr vs ₹689 Cr prior year)
Validation batches for 3 projects driving CS growth at 50%
METCS segment grew significantly; validation batch contribution acknowledged but sustainability unclear
Three major capex projects ~70% capitalized (₹1,400 Cr of ₹2,000 Cr)
MET₹1,223 Cr capitalized in H1; tracking towards ₹1,400 Cr guidance
Material cost reduced from 40% to 32% due to improved mix
METNet material consumption 32% in H1 vs 40% prior year; attributed to CS growth and backward integration
Earnings quality
What changed since the last call
Validation batch magnitude disclosed
NewCall revealed ~50% of CS growth from validation batches; prior guidance did not explicitly quantify this transient driver
Capex tracking ahead
Neutral₹1,223 Cr in H1 (vs ₹1,400 Cr H1+H2 guidance); implies final H1 run-rate sustainable, three projects on track
Forex headwind materialized
Downgrade₹20 Cr loss H1 FY27 vs ₹103 Cr gain H1 FY26; rupee weakness offset operational gains
Double-digit FY27 growth reaffirmed
NeutralNo upward revision; management hedged on H2 specifics, saying 'double-digit' but unwilling to quantify 10% vs 20%+
Peptide pipeline expanded
Upgrade60–70 projects now in pipeline vs ~40 prior disclosures; multiple SPPS lines under installation
The Q&A
Analysts pressed on validation batch sustainability, three projects' timelines, and margin guidance. Management disciplined: deflected specifics citing CDMO confidentiality, reiterated regulatory approval dependency, and refused to commit on EBITDA margin guidance despite 40%+ OPM. Tone was confident on execution but evasive on near-term catalysts.
Validation batch sustainability — Amey Chalke, JM Financial
PartialValidation batches ongoing; once validations complete, customers qualify and commercialize. Cannot quantify; mix will adjust as new projects ramp.
CS growth drivers — Surya Narayan Patra, PhilipCapital
PartialYes, CS higher due to validation execution. Several molecules in pre-validation, validation, and commercialization stages. Difficult to quantify exact timing.
Three projects update — Kunal Dhamesha, Macquarie
PartialCannot break down; 60–70 projects total at various phases. Three dedicated high-complexity projects, one very close to commercialization, two in next 1–2 quarters.
H2 FY27 growth outlook — Shyam Srinivasan, Goldman Sachs
PartialDouble-digit growth is the way forward. 17%, 10%, 20%? Cannot comment exactly. Will depend on commercialization cadence.
SPPS peptide capacity — Vivek Agrawal, Citigroup
DodgedTop three player globally, NDA in place. Small volume reactor, unlimited for us. Cannot disclose capacity specifics.
Capacity constraints — Shrikant Akolkar, Nuvama
Answered22 blocks Unit 1, 25 Unit 2, 6 Unit 3. Only 3 dedicated blocks across units. Capacity multipurpose, can be changed quickly. No shortage foreseen.
GLP-1 capex allocation — Chandrashekar, HIF Labs
DodgedCannot mention specific product names or allocations due to CDMO confidentiality. Based on RFPs, estimate ₹2,000 Cr ±20%.
Unit 3 capex risk — Neha Manpuria, Bank of America
AnsweredCapex divided uniformly across units. We actively invest based on customer interests, hand-in-hand contracts. No capacity shortage foreseen.
Peptide manufacturing complexity — Alankar Garude, Kotak
AnsweredLargest integrated player. Backward integrated to raw materials, TAGs, amino acids in-house. Center of excellence for purification. Capability and technology in place.
EBITDA margin guidance — Forams Parekh, BOB Capital
DodgedWish for consistency. Guidance is double-digit revenue growth, cannot comment on EBITDA level now.
Bonus shares — Vikal Gupta, Inspire Investment
DodgedBoard decision, not investor call commentary. Will hear information from the Board when time is right.
Peptide asset turns — Dhawal, Jefferies
PartialCannot comment on specific vertical. Multiple products under generics and CS. Difficult to disclose asset turn by segment due to CDMO confidentiality.
Resin sourcing in peptides — Arindam Mukherjee (individual)
PartialBackward integrated for peptide vertical; cannot disclose percentage due to CDMO confidentiality. Will disclose only generic APIs like naproxen.
Guidance
FY27 double-digit revenue growth assured
HighAlready delivered 35.4% YoY in Q2. Management reaffirmed for H2 but caveated on exact range (10%, 17%, 20%).
Gross margin ~60% all year (from FY27 call)
MediumNot explicitly reconfirmed in Q2 call. NPM 29.9% delivered; no gross margin disclosure.
EBITDA similar to FY26 (from FY27 call)
LowManagement refused to provide EBITDA guidance on this call despite 40%+ reported OPM. Evasive response to analyst Forams Parekh.
₹2,000 Cr total capex ±20% over 3 major projects
High₹1,223 Cr in H1 tracking towards ₹1,400 Cr expected for three projects. Management reaffirmed capex envelope on this call.
Risks the call surfaced
Validation batch cliff
High~50% of H1 CS growth from validation batches. Post-commercialization, base CS growth may revert to ~10% YoY, halving headline growth.
Project approval delays
HighThree major capex projects (₹2,000 Cr) timing tied to regulatory approval. Management stated 'next few quarters' but no firm dates. Delays could push commercialization to FY28.
Supply chain volatility
MediumRed Sea shipping disruptions, elevated air freight (fuel surcharges), and petrochemical-linked solvent price volatility. Management noted 'prices have remained elevated' and disruptions likely to persist.
FX headwind
MediumForex loss ₹20 Cr in H1 FY27 vs ₹103 Cr gain in H1 FY26. Rupee weakness eroding margins despite operational gains.
CDMO confidentiality blind spot
MediumCustomer confidentiality agreements prevent disclosure of product launches, segment details, and specific capex allocations. Limits forward visibility and analyst due diligence.
Management
Score 6/10. Disciplined but evasive. Clear on execution narrative and market positioning. Opaque on specifics: refuses to quantify product launches, capex allocations, or project timelines due to CDMO confidentiality. Strategic silence, not carelessness. Strong track record. 30-year history in CS. Q2 delivered 35.4% revenue, 64% PAT growth vs guidance. Capex ₹1,223 Cr in H1 tracking ₹2,000 Cr guidance. No major misses disclosed.
1 · Q3–Q4 FY27
Three major capex projects approach commercialization post-regulatory approval
2 · Q3–Q4 FY27
Peptide solid-phase (SPPS) capacity expansions (3,000L reactors) commissioned
3 · FY28
Capex cycle decelerates; cash generation improves from ₹800+ Cr in H1
Guidance was reaffirmed, not raised; regulatory approval timelines for the three projects remain uncertain.
Informational and educational content only. Not investment advice.